SCHEMBL2432068

SCHEMBL2432068

O=C(O)Cc1ccc2nc(-c3nccc4ccccc34)oc2c1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.44
RAB9A P51151 4/20 0.44
NPC1 O15118 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
GPR55 Q9Y2T6 1/20 0.44
TDP1 Q9NUW8 1/20 0.41
ALDH1A1 P00352 4/20 0.40
MAPT P10636 3/20 0.40
HPGD P15428 3/20 0.40
HSD17B10 Q99714 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPK1 P28482 1/20 0.40
CASP1 P29466 1/20 0.40
CYP2C19 P33261 1/20 0.40
CASP7 P55210 1/20 0.40
ATM Q13315 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ITGB1 P05556 2/20 0.39
ITGA4 P13612 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14592408 0.87 KDM4E (0.41) KDM4ERAB9ANPC1L3MBTL1GPR55
SCHEMBL2434007 0.79 NPC1 (0.44) KDM4ERAB9ANPC1L3MBTL1GPR55
SCHEMBL27578595 0.77 KDM4E (0.44) KDM4ERAB9ANPC1L3MBTL1GPR55
SCHEMBL27596539 0.77 KDM4E (0.41) KDM4ERAB9ANPC1L3MBTL1GPR55
SCHEMBL2429608 0.76 ITGB1 (0.55) KDM4ERAB9ANPC1L3MBTL1GPR55
SCHEMBL2432297 0.75 ITGB1 (0.47) ITGB1ITGA4
SCHEMBL2433190 0.73 ITGB1 (0.45) RAB9ANPC1TDP1ALDH1A1MAPT
SCHEMBL2430872 0.73 ITGB1 (0.58) KDM4ERAB9ANPC1L3MBTL1ALDH1A1
SCHEMBL3589064 0.69 CYP1A2 (0.49) KDM4ERAB9ATDP1ALDH1A1MAPT
SCHEMBL3739311 0.68 TDP1 (0.53) KDM4ERAB9ANPC1L3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-20040110945-A1 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1346982-A1 VLA-4 INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110945-A1 Vla-4 inhibitors VCAM1, ITGA1, ITGB4 KDM4E 1271/4885RAB9A 2530/4885NPC1 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.